ArticleBrain and behavior2025
Basic Fibroblast Growth Factor-Releasing Bioabsorbable Polyglycolic Acid Dura Mater Enhances Neural Progenitor Cell Proliferation and Neuroprotection After Brain Injury.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundTraumatic brain injury harms health, causes disability, and burdens health care systems and economies. Although new treatments for brain injury have been developed, their therapeutic efficacy remains insufficient. Herein, we demonstrate the therapeutic efficacy of artificial dura mater with varying basic fibroblast growth factor (bFGF)-releasing capabilities using a brain injury model.
methodsArtificial dura mater of lower (FGF-L) and higher (FGF-H) bFGF-releasing capabilities was prepared via oxygen plasma treatment for polyglycolic acid nonwoven fabric followed by bFGF adsorption. Mice received either bFGF-releasing dura mater (FGF-L, FGF-H) or bFGF-free dura mater (FGF-C) at the site of the induced brain injury.
resultsNeurological functions significantly improved in the FGF-L and FGF-H groups compared with those in the FGF-C group on Day 14. No significant difference was observed in the brain injury area between the FGF-C group and either the FGF-L or FGF-H group. The number of SRY-box transcription factor 2-positive cells in the cortex was significantly larger in the FGF-L and FGF-H groups than in the FGF-C group on Day 7. The terminal transferase dUTP nick-end labeling-positive cell ratio was significantly lower in the FGF-H group than in the FGF-C group on Day 14. The occludin-positive and ZO-1-positive cell ratios were significantly greater in the FGF-H group than in the FGF-C group on Day 14, suggesting improved blood-brain barrier integrity.
conclusionThe bFGF-releasing dura mater enhanced neural progenitor cell proliferation, inhibited apoptosis and blood-brain barrier breakdown, and contributed to neurological function recovery in brain-injured mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.